Vericel Corp (VCEL) bonds
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/30240% above fair value
$56.96−0.46 (-0.80%)
Close on Nov 13, 2026Market cap $2.92BP/E 96.5Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Vericel reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Vericel's 10-Q for the period ended Jul 29, 2022
Vericel's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Letter of credit | $15.00M |
| Revolving credit facility | $150.00M |
See a number that looks wrong?